Wall Street analysts predict that TherapeuticsMD Inc (NASDAQ:TXMD) will post earnings per share of ($0.10) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for TherapeuticsMD’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.11). TherapeuticsMD posted earnings of ($0.11) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The firm is expected to announce its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that TherapeuticsMD will report full year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.69) to $0.18. For the next fiscal year, analysts expect that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.35) to $0.24. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $4.66 million. TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. TherapeuticsMD’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.12) earnings per share.
Several brokerages have recently weighed in on TXMD. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 7th. Oppenheimer reiterated a “buy” rating and issued a $10.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 28th. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, Deutsche Bank set a $9.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $14.50.
Institutional investors have recently bought and sold shares of the stock. MANA Advisors LLC purchased a new position in TherapeuticsMD during the fourth quarter worth about $104,000. Paloma Partners Management Co purchased a new position in TherapeuticsMD during the fourth quarter worth about $105,000. Edge Wealth Management LLC grew its position in TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after buying an additional 20,000 shares in the last quarter. Claraphi Advisory Network LLC purchased a new position in TherapeuticsMD during the fourth quarter worth about $275,000. Finally, Teacher Retirement System of Texas grew its position in TherapeuticsMD by 332.0% during the fourth quarter. Teacher Retirement System of Texas now owns 58,000 shares of the company’s stock worth $350,000 after buying an additional 44,574 shares in the last quarter. Institutional investors and hedge funds own 73.31% of the company’s stock.
Shares of NASDAQ TXMD traded up $0.01 during mid-day trading on Friday, hitting $5.83. The company had a trading volume of 1,213,257 shares, compared to its average volume of 1,937,715. The stock has a market cap of $1,237.81, a PE ratio of -15.92 and a beta of 1.36. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $7.01.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.